Live ticker
Activity
Every trade on Endcap, live. The tape updates in place as new positions clear.
50 trades
- @blakevargasBoughtYESat 63¢+78 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @caseyokaforBoughtYESat 42¢+43 SPon Most-funded GLP-1 weight-loss app of 2026: Sequence (WW)
- @rileykimBoughtYESat 69¢+18 SPon Generic GLP-1 launch in US: 2027 or later
- @sashavargasBoughtYESat 62¢+37 SPon First GLP-1 brand to 1M active subscribers: Sequence
- @tatumchenBoughtYESat 40¢+54 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Eli Lilly (tirzepatide)
- @haydenlopezBoughtYESat 53¢+30 SPon Generic GLP-1 launch in US: Q3 2026
- @sashavargasBoughtYESat 83¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Sequence (Weight Watchers)
- @frankieblakeBoughtYESat 59¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Found
- @parkerokaforBoughtYESat 59¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Hims
- @skylercarrilloBoughtYESat 62¢+63 SPon First GLP-1 telehealth to raise a mega-round in 2026: Calibrate
- @juneyoonBoughtYESat 57¢+21 SPon Tirzepatide compounding outcome: Full ban with no shortage carve-out
- @darbyblakeBoughtYESat 52¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: PlushCare
- @rowanmonroeBoughtYESat 52¢+63 SPon First GLP-1 telehealth to raise a mega-round in 2026: Ro
- @harperyoonBoughtYESat 57¢+60 SPon Tirzepatide compounding outcome: Expanded permissions
- @tatumkimBoughtYESat 64¢+16 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Tied within 1pp
- @briarlopezBoughtYESat 55¢+24 SPon First GLP-1 telehealth to raise a mega-round in 2026: Hims
- @tatumwalshBoughtYESat 57¢+46 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @elliotalvarezBoughtYESat 49¢+27 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @logantorresBoughtYESat 71¢+60 SPon Generic GLP-1 launch in US: Q4 2026
- @kaiunderhillBoughtYESat 73¢+36 SPon Generic GLP-1 launch in US: Q2 2026
- @marloweriveraBoughtYESat 49¢+17 SPon Tirzepatide compounding outcome: Status quo (compounding continues)
- @skylercarrilloBoughtYESat 45¢+69 SPon First GLP-1 brand to 1M active subscribers: Found
- @darbyblakeBoughtYESat 57¢+45 SPon First GLP-1 telehealth to raise a mega-round in 2026: Calibrate
- @skylerunderhillBoughtYESat 44¢+63 SPon First GLP-1 telehealth to raise a mega-round in 2026: PlushCare
- @drewhayesBoughtYESat 52¢+43 SPon First GLP-1 telehealth to raise a mega-round in 2026: Found
- @skylerunderhillBoughtYESat 59¢+16 SPon First GLP-1 brand to 1M active subscribers: Sequence
- @kaipatelBoughtYESat 63¢+67 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Tied within 1pp
- @rowandiazBoughtYESat 71¢+58 SPon Generic GLP-1 launch in US: Q2 2026
- @marloweriveraBoughtYESat 53¢+22 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @lanewalshBoughtYESat 81¢+74 SPon First GLP-1 telehealth to raise a mega-round in 2026: Sequence (Weight Watchers)
- @parkerokaforBoughtYESat 54¢+21 SPon Generic GLP-1 launch in US: Q2 2026
- @parkerokaforBoughtYESat 53¢+29 SPon First GLP-1 telehealth to raise a mega-round in 2026: Sequence (Weight Watchers)
- @tatumchenBoughtYESat 72¢+66 SPon Generic GLP-1 launch in US: Q4 2026
- @skylerpowellBoughtYESat 39¢+58 SPon First GLP-1 brand to 1M active subscribers: Calibrate
- @rowanmonroeBoughtYESat 61¢+60 SPon First GLP-1 telehealth to raise a mega-round in 2026: Hims
- @kaipatelBoughtYESat 72¢+43 SPon Generic GLP-1 launch in US: 2027 or later
- @emersonhayesBoughtYESat 66¢+20 SPon Most-funded GLP-1 weight-loss app of 2026: Calibrate
- @sashahayesBoughtYESat 54¢+35 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Novo Nordisk (semaglutide)
- @sashavargasBoughtYESat 52¢+16 SPon GLP-1 telehealth that consolidates first in 2026: Calibrate
- @caseyokaforBoughtYESat 48¢+52 SPon Most-funded GLP-1 weight-loss app of 2026: Hims Weight Loss
- @kaiunderhillBoughtYESat 69¢+80 SPon Tirzepatide compounding outcome: Restricted with shortage carve-out
- @drewhayesBoughtYESat 53¢+72 SPon First GLP-1 telehealth to raise a mega-round in 2026: Calibrate
- @logantorresBoughtYESat 68¢+61 SPon Generic GLP-1 launch in US: Q2 2026
- @tatumkimBoughtYESat 78¢+27 SPon First GLP-1 telehealth to raise a mega-round in 2026: Sequence (Weight Watchers)
- @noelyoonBoughtYESat 50¢+21 SPon First retailer to launch private-label GLP-1 program 2026: CVS
- @morgansantosBoughtYESat 55¢+30 SPon Tirzepatide compounding outcome: Full ban with no shortage carve-out
- @lanepowellBoughtYESat 59¢+67 SPon First GLP-1 brand to 1M active subscribers: No brand discloses
- @alexalvarezBoughtYESat 69¢+80 SPon Generic GLP-1 launch in US: Q4 2026
- @finleyyoonBoughtYESat 51¢+16 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Novo Nordisk (semaglutide)
- @lanejensenBoughtYESat 56¢+37 SPon Tirzepatide compounding outcome: Expanded permissions